Glycerol
Glycerol (glycerin) is an osmotic agent used as a rectal suppository or enema for the short-term relief of constipation, and also has applications as an emollient and pharmaceutical excipient.
Adult dose
Dose adjustments
Not stated in the retrieved sections.
Not stated in the retrieved sections.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Known hypersensitivity to glycerol
- Adult-size suppositories are not suitable for use by children and infants (§4.3)
- Not to be swallowed — suppositories must not be taken by mouth (§4.4)
Side effects
- Gastrointestinal disorders: may cause irritation and occasionally abdominal cramps (§4.8, the whole adverse-effect statement)
Interactions
- None known (§4.5)
Clinical monograph
How it works
When administered rectally it acts as a hyperosmotic and mild local irritant, drawing water into the bowel and stimulating rectal evacuation.
Prescribing in practice
- It is intended for short-term relief of occasional constipation; persistent or recurrent symptoms warrant assessment for an underlying cause rather than continued laxative use.
- Rectal preparations may cause local irritation or a burning sensation on administration.
- Moistening the suppository before insertion can aid administration and patient comfort.
Monitoring
Routine laboratory monitoring is not required; review the response and reassess if constipation persists despite treatment.
Counselling the patient
- This is for short-term relief; see your clinician if constipation continues or recurs.
- Maintaining adequate fluid intake, fibre and activity helps prevent constipation.
Evidence & guidelines
Osmotic and stimulant laxatives are established options for the management of constipation in line with NICE guidance.
Reference: NICE CKS constipation; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021